Literature DB >> 20847608

[Portal hypertensive gastropathy and gastric antral vascular ectasia].

Won Hyeok Choe1.   

Abstract

Portal hypertensive gastropathy (PHG) is a term used to define the endoscopic findings of gastric mucosa with a characteristic mosaic-like pattern with or without red spots, and a common finding in patients with portal hypertension. These endoscopic findings correspond to dilated mucosal capillaries without inflammation. The pathogenesis of PHG in not well known, but portal hypertension and some humoral factors seem to be crucial factors for its development. Pharmacological (e.g. propranolol), or interventional radiological (such as transjugular intrahepatic portosystemic shunt) procedures may be useful in preventing re-bleeding from PHG. The classic features of gastric antral vascular ectasia (GAVE) syndrome include red, often haemorrhagic lesions predominantly located in the gastric antrum which can result in significant blood loss. Although the pathogenesis of GAVE is not clearly defined, it seems to be a separate disease entity from PHG, because GAVE generally does not respond to a reduction of portal pressures. Endoscopic ablation (such as argon plasma coagulation) is the first-line treatment of choice. This review will focus on the incidence, clinical importance, etiology, pathophysiology, and treatment of PHG and GAVE syndrome in the setting of portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847608     DOI: 10.4166/kjg.2010.56.3.186

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  2 in total

1.  KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2020-01-10

2.  IL-6-driven FasL promotes NF-κBp65/PUMA-mediated apoptosis in portal hypertensive gastropathy.

Authors:  Siwei Tan; Minyi Xu; Bilun Ke; Yu Lu; Huiling Liu; Jie Jiang; Bin Wu
Journal:  Cell Death Dis       Date:  2019-10-03       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.